+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Thin Film Drugs Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4987127
  • Report
  • February 2020
  • Region: Global
  • 120 pages
  • Mordor Intelligence
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AdhexPharma
  • Aquestive Therapeutics
  • ARx, LLC.
  • Indivior PLC
  • INTELGENX CORP
  • Pfizer, Inc.
  • MORE
The thin film drug market studied was projected to grow with a CAGR of nearly 9.3% over the forecast period. The increasing demand for an effective way of drug delivery and the drawbacks associated with the conventional forms of dosage are the major factors propelling the growth of the market. The thin films are believed to be convenient to swallow, self-administrable, and fast dissolving dosage form, all of which make it a versatile platform for drug delivery. There are several routes of delivery oral, buccal, sublingual, ocular, and transdermal routes. Furthermore, the growing investments in research and development programs by the pharmaceutical companies are boosting the market growth. However, the various substitute drugs available is the major drawback for market growth.

Key Market Trends

Oral Thin Film Drugs Segment Holds the Major Share Followed by Transdermal Thin Film
  • Oral thin film drugs are placed on a patient’s oral mucosal tissue or tongue, which gets wet by saliva and swiftly hydrates and adheres to the site of application. This degenerates within a few seconds to promote oromucosal absorption. These drugs present high therapeutic index with good physical properties such as sharper disintegration and dissolution. Furthermore, the oral thin film drug delivery system lets to bypass the first pass metabolism and ensures higher bioavailability.
  • Demand for oral thin film drugs has been growing across the world due to technological advancements in these products. Many research and development programs are being conducted to improve the segment of drug delivery.
  • The major factors boosting the segment are increasing demand for these efficient ways of drug delivery and increasing funding for pharmaceutical research.
North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall thin film drug market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, advanced technologies used in the pharmaceutical research and development for the discovery of novel drug delivery technique. Furthermore, rising demand for efficient drug delivery routes and its adequacy in the region would further drive the thin film drug market in the future. Moreover, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase the market growth.

Competitive Landscape

The thin film drugs market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are ZIM Laboratories Limited, Aquestive Therapeutics, Indivior PLC, Tesa Labtec GmbH, Pfizer, Inc., ARx, LLC., Solvay, AdhexPharma, IntelGenx.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AdhexPharma
  • Aquestive Therapeutics
  • ARx, LLC.
  • Indivior PLC
  • INTELGENX CORP
  • Pfizer, Inc.
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Demand for Effective Drug Delivery Systems
4.2.2 Increasing Investments for Pharmaceutical Developments
4.3 Market Restraints
4.3.1 Availability of Substitute Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 By Product Type
5.1.1 Oral Thin Film
5.1.2 Transdermal Thin Film
5.2 By Indication
5.2.1 Schizophrenia
5.2.2 Migraine
5.2.3 Opioid Dependence
5.2.4 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles
6.1.1 ZIM Laboratories Limited
6.1.2 Aquestive Therapeutics
6.1.3 Indivior PLC
6.1.4 Tesa Labtec GmbH
6.1.5 Pfizer, Inc.
6.1.6 ARx, LLC.
6.1.7 Solvay
6.1.8 AdhexPharma
6.1.9 INTELGENX CORP

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • ZIM Laboratories Limited
  • Aquestive Therapeutics
  • Indivior PLC
  • Tesa Labtec GmbH
  • Pfizer, Inc.
  • ARx, LLC.
  • Solvay
  • AdhexPharma
  • INTELGENX CORP
Note: Product cover images may vary from those shown
Adroll
adroll